An SGLT2 inhibitor combined with a nonsteroidal mineralocorticoid receptor antagonist quickly cut urinary ...

Moderna convinced a U.S. appeals court on Wednesday to uphold a ruling that undercut patent infringement claims by biotech ...

H.C. Wainwright’s Patrick Trucchio reiterated his Buy rating on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and raised his ...

Alnylam Pharmaceuticals Inc. won’t get another chance at its patent infringement suit against Moderna Inc. over its mRNA Covid-19 vaccine, a federal appeals court ruled Wednesday.

Alnylam Pharmaceuticals has put its dancing shoes on to raise awareness of the experience of living with acute hepatic ...

Goldman Sachs analysts led by Steven Kron share the firm's latest conviction list, which includes 23 of the bank's top picks ...

CM, offers strong efficacy and a favorable safety profile compared to competitors. See why I rate ALNY stock a Hold.

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

Acting USPTO Director Coke Morgan Stewart institutes sua sponte review of a PTAB decision in favor of TikTok; the Federal ...

CAMBRIDGE, Mass., May 28, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman ...

Biogen Inc. is teaming up with a new startup launched by Alnylam Pharmaceuticals’ founding CEO John Maraganore.

Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 20 years ago, it would be worth $38,973.12 today based on ...